Cabaletta Bio, Inc. (CABA)
Total Valuation
Cabaletta Bio has a market cap or net worth of $827.34 million. The enterprise value is $591.11 million.
Market Cap | 827.34M |
Enterprise Value | 591.11M |
Important Dates
The last earnings date was Thursday, March 21, 2024, before market open.
Earnings Date | Mar 21, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Cabaletta Bio has 48.24 million shares outstanding. The number of shares has increased by 47.69% in one year.
Shares Outstanding | 48.24M |
Shares Change (YoY) | +47.69% |
Shares Change (QoQ) | +7.65% |
Owned by Insiders (%) | 3.14% |
Owned by Institutions (%) | 101.54% |
Float | 39.40M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 3.50 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.29, with a Debt / Equity ratio of 0.02.
Current Ratio | 15.29 |
Quick Ratio | n/a |
Debt / Equity | 0.02 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -40.80% and return on invested capital (ROIC) is -30.95%.
Return on Equity (ROE) | -40.80% |
Return on Assets (ROA) | -37.90% |
Return on Capital (ROIC) | -30.95% |
Revenue Per Employee | n/a |
Profits Per Employee | -$670,050 |
Employee Count | 101 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +126.26% in the last 52 weeks. The beta is 2.46, so Cabaletta Bio's price volatility has been higher than the market average.
Beta (1Y) | 2.46 |
52-Week Price Change | +126.26% |
50-Day Moving Average | 21.31 |
200-Day Moving Average | 16.98 |
Relative Strength Index (RSI) | 30.82 |
Average Volume (30 Days) | 918,960 |
Short Selling Information
The latest short interest is 7.09 million, so 14.70% of the outstanding shares have been sold short.
Short Interest | 7.09M |
Short Previous Month | 7.01M |
Short % of Shares Out | 14.70% |
Short % of Float | 18.00% |
Short Ratio (days to cover) | 8.10 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -74.66M |
Pretax Income | -67.68M |
Net Income | -67.68M |
EBITDA | -64.18M |
EBIT | -67.68M |
Earnings Per Share (EPS) | -$1.65 |
Balance Sheet
The company has $241.25 million in cash and $5.02 million in debt, giving a net cash position of $236.23 million or $4.90 per share.
Cash & Cash Equivalents | 241.25M |
Total Debt | 5.02M |
Net Cash | 236.23M |
Net Cash Per Share | $4.90 |
Equity / Book Value | 236.20M |
Book Value Per Share | 4.90 |
Working Capital | 228.50M |
Cash Flow
In the last 12 months, operating cash flow was -$53.55 million and capital expenditures -$687,000, giving a free cash flow of -$54.24 million.
Operating Cash Flow | -53.55M |
Capital Expenditures | -687,000 |
Free Cash Flow | -54.24M |
FCF Per Share | -$1.27 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Cabaletta Bio does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -47.69% |
Shareholder Yield | -47.69% |
Earnings Yield | -8.18% |
FCF Yield | -6.56% |
Analyst Forecast
The average price target for Cabaletta Bio is $32.88, which is 92.73% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $32.88 |
Price Target Difference | 92.73% |
Analyst Consensus | Strong Buy |
Analyst Count | 8 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | -41.86% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 3 |